Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £451,250 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia in adults. The funding, raised through an allotment of new ordinary shares to CEO Vladislav Sandler, reflects investor confidence in the company’s long-term value and supports the momentum of its clinical development without diluting shareholder value.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a clinical stage biopharmaceutical company based in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 38,023
Technical Sentiment Signal: Sell
Current Market Cap: £7.52M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.